bioAffinity Technologies (BIAF) risk factors
Item 1A of every bioAffinity Technologies, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors65 risks2 new9 dropped5 reworded
Accumulated deficit grew to $68.6 million alongside a $14.9 million net loss in 2025. PPLS generated $6.2 million in 2025 revenue. Clinical trial execution and management retention remain core operational risks.
Filed Mar 16, 2026 - FY2024 10-K risk factors72 risks
The company has a limited operating history with an accumulated deficit of $53.6 million and $1.1 million cash on hand as of December 31, 2024. Revenue grew from $2.5 million in 2023 to $9.4 million in 2024, driven entirely by its PPLS laboratory subsidiary offering the CyPath Lung test. The company faces going concern doubts and must raise additional capital, secure FDA clearance, and manage a single laboratory facility in San Antonio, Texas.
Filed Mar 31, 2025